PSA (Prostate-Specific Antigen) is a serine protease secreted by prostate epithelial cells, used to assess prostate health and screen for prostate cancer in men. Elevated PSA can signal cancer, but also benign prostatic hyperplasia, prostatitis, infection, or recent urological instrumentation—making shared decision-making with a clinician essential rather than automatic screening.
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring. Not a stand-alone diagnosis.
PSA screening is a personal decision, not an automatic recommendation—especially in Europe. The ERSPC (European Randomized Study of Screening for Prostate Cancer) trial showed PSA screening reduces prostate cancer mortality, but with significant overdiagnosis: for every prostate cancer death prevented, approximately 36 men receive a diagnosis they might never have had symptoms from.
You may consider testing if you have a family history of prostate cancer, are over 50 (or 45 with family history), and are willing to discuss both benefits and harms with a clinician. In Sweden, PSA is offered on request rather than as an organized screening program. The conversation should focus on shared decision-making: your individual risk factors, life expectancy, tolerance for false positives, and values around treatment.
Flags prostate disease. Elevated PSA can indicate cancer, benign prostatic hyperplasia (BPH), prostatitis, or urinary tract infection—prompting further investigation when levels are abnormal.
Supports early detection pathways. When PSA is elevated, modern adjuncts like multiparametric MRI (mpMRI) before biopsy significantly reduce unnecessary biopsies per the PROMIS trial, improving diagnostic accuracy.
Tracks prostate health longitudinally. Serial PSA measurements over years reveal velocity (rate of change), which helps distinguish aggressive disease from indolent elevation—a sharper signal than a single value.
Informs shared decision-making. PSA context (total PSA, free/total ratio, PSA density, PSA velocity) helps men and their clinicians weigh surveillance, active monitoring, and intervention options if cancer is found.
Contextualizes other hormonal markers. PSA sits within a broader hormonal picture—elevated testosterone or SHBG changes can influence prostate physiology, making PSA interpretation more nuanced when viewed alongside these markers.
Biology and function. Prostate-specific antigen is a serine protease (enzyme) produced by prostate epithelial cells. Its primary physiological role is to liquefy seminal fluid after ejaculation. It normally circulates in very low concentrations in blood; elevated blood PSA signals either prostate cell damage, inflammation, or uncontrolled proliferation.
Why it rises beyond cancer. PSA levels increase not only with cancer but with any disruption to the prostate's architecture: benign prostatic hyperplasia (age-related gland enlargement that affects ~50% of men by age 50), acute or chronic prostatitis (infection or inflammation), urinary tract infection, recent digital rectal exam, vigorous cycling, or even ejaculation within 48 hours. This high non-cancer specificity is PSA's major limitation—a finding that prompted the European approach to emphasize shared decision-making and modern adjuncts like mpMRI rather than immediate biopsy.
Mortality benefit is real but modest. The ERSPC trial demonstrated a 21% relative reduction in prostate cancer-specific mortality with screening. However, this translates to ~1 life saved for every 500–1000 men screened—a small absolute benefit offset by overdiagnosis of indolent cancers.
Overdiagnosis is the elephant in the room. Many prostate cancers grow slowly and never cause harm in the man's lifetime. ERSPC found ~36 additional diagnoses per cancer death prevented. This drives unnecessary anxiety, biopsies, active surveillance visits, and sometimes overtreatment—side effects include incontinence and erectile dysfunction that genuinely harm quality of life.
Modern refining tools reduce harm. mpMRI, free/total PSA ratio, PSA velocity, and PSA density substantially reduce unnecessary biopsies and help distinguish aggressive from indolent disease—the PRECISION trial showed mpMRI before biopsy cuts overdiagnosis significantly.
Standard Swedish healthcare reference (vårdcentralen): < 4 ng/mL is typically considered normal across all ages. However, age-adjusted ranges better reflect baseline prostate volume and are preferred in modern interpretation.
Age-adjusted ranges (European consensus): < 2.5 ng/mL (age 40–49), < 3.5 ng/mL (age 50–59), < 4.5 ng/mL (age 60–69), < 6.5 ng/mL (age 70+). These thresholds recognize that larger, benign prostates produce more PSA.
Loovi proactive interpretation: PSA values at the upper edge of age-adjusted ranges warrant careful discussion with your clinician rather than automatic surveillance. Serial testing (annual or biennial) allows PSA velocity assessment—a rise > 0.75 ng/mL per year suggests faster prostate changes and warrants investigation.
The key message: PSA is not a binary threshold. It's a signal whose meaning depends on age, prostate size, free/total PSA ratio, and most importantly, the man's own values and life expectancy.
PSA < 2.5 ng/mL (age-adjusted low). This is genuinely reassuring for prostate cancer risk in the near term. Most men with PSA < 2.5 ng/mL and no family history do not need screening for many years. If retesting, annual or biennial intervals are low-yield unless PSA velocity rises sharply.
PSA 2.5–4.0 ng/mL (age-adjusted normal-to-upper-range). This is the gray zone where ~25% of men harbor undetected cancer, but the vast majority have benign disease or no disease at all. The conversation pivots to shared decision-making: prostate size (via rectal exam or ultrasound), free/total PSA ratio (a higher ratio suggests benign enlargement; < 25% free PSA raises cancer concern), PSA velocity over time, and family history. Modern practice favors mpMRI before biopsy to reduce unnecessary needle procedures.
PSA 4.0–10 ng/mL (elevated). This warrants clinical conversation. The cancer risk rises with absolute level and free/total ratio, but benign causes (BPH, prostatitis, recent trauma) account for most elevations. Free PSA ratio > 25% and mpMRI findings help triage biopsy candidacy. PSA density (PSA divided by prostate volume) also refines risk: a high density is more concerning.
PSA > 10 ng/mL (significantly elevated). Cancer risk rises substantially. Urgent multidisciplinary evaluation, including free/total PSA, mpMRI, urine biomarkers (4Kscore, PHI), and possibly biopsy, is appropriate. However, acute infection or instrumentation can transiently elevate PSA—recheck after 4–6 weeks if a recent urinary procedure occurred.
Factors that influence PSA. Recent ejaculation (within 48 hours), vigorous cycling or trauma (> 24 hours of activity), digital rectal exam or urological instrumentation, acute urinary tract infection or prostatitis. Recheck PSA 4–6 weeks after any acute trigger to ensure baseline stability.
Genetics and age. Prostate size increases with age and is influenced by androgen receptor genetics and local DHT signaling. Larger prostate = higher baseline PSA. Family history of early prostate cancer raises the risk that elevated PSA signals malignancy rather than benign enlargement.
Benign prostatic hyperplasia (BPH). Age-related enlargement of the prostate gland, affecting ~50% of men over 50, raises PSA proportionally. BPH is not cancer and not dangerous—only problematic if it obstructs urinary flow. Total testosterone and SHBG status influence DHT accumulation in the prostate and may correlate with BPH severity, though causality is complex.
Prostatitis and infection. Acute bacterial prostatitis, chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and urinary tract infection all cause acute PSA elevation. These typically resolve 4–6 weeks after the infection clears.
Trauma and instrumentation. Urological procedures (cystoscopy, catheterization, transurethral resection of the prostate), vigorous cycling, or recent ejaculation transiently raise PSA. Allow 48 hours after ejaculation and > 24 hours after intense cycling before testing for a stable baseline.
Prostate cancer. Malignant transformation increases PSA secretion—though velocity and free/total ratio are more specific than absolute value. Aggressive cancers (Gleason > 7) produce higher PSA and warrant urgent evaluation.
Lifestyle pillars for prostate health. The same factors that optimize cardiovascular and metabolic health—regular exercise, stress management, sleep, and an anti-inflammatory diet—also support prostate health. Exercise reduces BPH risk and improves urinary flow. Sleep and stress management modulate chronic inflammation and androgen signaling. Mediterranean and DASH-style diets are associated with lower prostate cancer risk in epidemiological studies, likely through reduced chronic inflammation and improved lipid metabolism.
Moderate alcohol and reduce smoking. Heavy alcohol increases prostate inflammation risk, while smoking is linked to more aggressive prostate cancer. Moderation aligns with broader health goals.
Pharmacological approaches. If BPH or elevated PSA is due to DHT-driven enlargement, 5-alpha reductase inhibitors (finasteride, dutasteride) reduce DHT conversion and lower PSA by ~25% over months. Alpha-blockers (tamsulosin, alfuzosin) improve urinary flow but don't directly lower PSA. These are prescribed only when urinary symptoms warrant treatment—not for PSA reduction alone.
The truth is that PSA optimization is largely about systemic health—the same factors that support cardiovascular longevity, metabolic stability, and robust immunity support prostate health. Individual risk profiles, prostate genetics, and hormonal status vary widely, which is why personalized evaluation with a longevity doctor matters far more than a generic checklist.
A single PSA value—even if normal—is a clinical half-measure without context. PSA needs to be interpreted alongside total testosterone, SHBG, and free testosterone (which influence prostate physiology and DHT accumulation), creatinine and eGFR (renal function can affect how PSA is cleared), and even albumin (PSA is bound to albumin and other proteins in circulation, and low albumin can artificially raise free PSA). More broadly, prostate cancer risk doesn't exist in isolation—it sits within cardiovascular risk, metabolic health, chronic inflammation status, and family history.
This is why Loovi's approach to longevity tracking matters. We measure 120+ biomarkers annually, allowing us to see PSA in the context of your full inflammatory profile (hs-CRP, IL-6), your metabolic baseline (HbA1c, fasting insulin, triglycerides), your lipid architecture (ApoB, Lp(a)), and your hormonal landscape (total and free testosterone, SHBG, cortisol). Combined with physical tests—VO2 max, strength, mobility—and unrushed consultations with a longevity doctor, this systems-view transforms PSA from a source of anxiety into one piece of a personalized health strategy. You get shared decision-making, modern adjuncts like mpMRI when needed, and clarity on whether surveillance, active monitoring, or other paths make sense for your values and risk profile.
This is a shared decision between you and your clinician. The ERSPC trial showed PSA screening reduces prostate cancer mortality by ~21%, but with overdiagnosis of indolent cancers. In Sweden, organized screening is not routine—screening is offered on request. Discuss your family history, life expectancy, and comfort with the possibility of detecting a slow-growing cancer that might never harm you.
Standard PSA tests measure total PSA—all PSA in circulation, both protein-bound and free. Free PSA is the fraction not bound to protein. The free/total PSA ratio helps distinguish cancer (lower ratio, < 25% free) from benign disease (higher ratio, > 25% free). If your total PSA is borderline elevated, your clinician may order free PSA to refine cancer risk assessment before deciding on biopsy or mpMRI.
PSA velocity is the rate of annual change in PSA. A rise > 0.75 ng/mL per year suggests faster prostate changes and warrants investigation, even if absolute PSA is still in the normal range. Velocity can distinguish fast-growing cancer from stable, benign enlargement. This is why serial measurement over years is more informative than a single PSA result.
The ERSPC trial showed a 21% relative reduction in prostate cancer-specific mortality with PSA screening. However, this is offset by overdiagnosis—the trial found ~36 additional cancer diagnoses per death prevented. Modern refining tools (mpMRI, free PSA ratio, biomarkers like PHI and 4Kscore) reduce overdiagnosis and help focus intervention on truly aggressive disease.
Feeling fine is not reassurance—prostate cancer is often asymptomatic early on. High PSA warrants a conversation with your clinician about next steps: free/total PSA ratio, PSA density, mpMRI before biopsy (not automatic biopsy), and discussion of your values around surveillance vs. intervention. The modern approach is thoughtful risk stratification, not knee-jerk procedures.
Wait at least 48 hours after ejaculation to ensure a stable PSA baseline. Ejaculation transiently raises PSA. Similarly, vigorous cycling and urological procedures should be at least > 24 hours or 4–6 weeks prior (respectively) to allow PSA to settle.
Yes. Testosterone is converted to DHT in the prostate, and DHT stimulates prostate cell growth. Higher testosterone and lower SHBG (which increases free testosterone availability) are associated with larger prostate and higher PSA. However, androgen deprivation therapy (used in prostate cancer treatment) lowers PSA—this doesn't mean testosterone causes cancer, but it does mean testosterone influences prostate biology and PSA production.
PSA is not part of routine organized screening in Sweden, but it is available on request at most vårdcentral clinics. In some regions, pilot organized screening programs are being tested. Loovi provides PSA testing through our 80+ clinic network as part of the comprehensive biomarker panel, allowing you to make a shared decision with your clinician or Loovi doctor about whether screening makes sense for you.
Multiparametric MRI visualizes the prostate directly and can identify suspicious lesions before biopsy. The PRECISION trial showed mpMRI before biopsy cut unnecessary biopsies by ~30% and reduced overdiagnosis of indolent cancer. When PSA is borderline elevated or concerning, modern practice favors mpMRI first to triage biopsy candidacy rather than automatic needle biopsy.
